Volume 21, Number 11—November 2015
Research
Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 31
Table 2
NATs to HPeV types 1, 3, and 6 in intravenous immunoglobulin preparations commercially available in Japan*
Preparation | Country† | Year obtained | IVIG treatment | NATs |
||
---|---|---|---|---|---|---|
HPeV1 | HPeV3 | HPeV6 | ||||
Batch 1 | Japan | 2010, 2011 | PEG | 1:1,024 | 1:512 | 1:2,048 |
Batch 2 | Japan | 2010 | Freeze-dried PEG | 1:1,024 | 1:512 | 1:1,024 |
Batch 3-1 | Japan | 2011 | Sulfonation | 1:1,024 | 1:512 | 1:2,048 |
Batch 3-2 | Japan | 2011, 2012 | Sulfonation | 1:1,024 | 1:1,024 | 1:2,048 |
Batch 4 | United States | 2012 | Ion-exchange resin | 1:1,024 | 1:512 | 1:2,048 |
Batch 5 | Germany | 2012 | pH4 | 1:2,048 | 1:512 | 1:2,048 |
*HPeV1, human parechovirus type 1; IVIG, intravenous immunoglobulin; NATs, neutralizing antibody titers; PEG, polyethylene glycol.
†Country where IVIG was obtained.
1Presented in part at IDWeek, October 8–12, 2014, Philadelphia, Pennsylvania, USA.